GeneDx Forecast, price target & analysts
GeneDx Target price 2026 - Analyst rating & recommendation
GeneDx Classifications & Recommendation
GeneDx Price Target
| Target Price | $91.80 |
| Price | $88.48 |
| Potential |
3.75%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target GeneDx 2027 .
The average GeneDx target price is $91.80.
This is
3.75%
register free of charge
$108.15
22.23%
register free of charge
$74.74
15.53%
register free of charge
|
|
| A rating was issued by 13 analysts: 12 Analysts recommend GeneDx to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the GeneDx stock has an average upside potential 2027 of
3.75%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2031
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 427.54 | 486.81 |
| 39.97% | 13.86% | |
| EBITDA Margin | -2.07% | 1.66% |
| 18.49% | 180.28% | |
| Net Margin | -4.92% | 0.61% |
| 71.28% | 112.41% |
11 Analysts have issued a sales forecast GeneDx 2026 . The average GeneDx sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an GeneDx EBITDA forecast 2026. The average GeneDx EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 GeneDx Analysts have issued a net profit forecast 2026. The average GeneDx net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2031
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.73 | 0.10 |
| 62.37% | 113.70% | |
| P/E | 857.89 | |
| EV/Sales | 5.41 |
11 Analysts have issued a GeneDx forecast for earnings per share. The average GeneDx EPS is
This results in the following potential growth metrics and future valuations:
Current GeneDx Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jun 29 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Jun 23 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 05 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | May 05 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | May 05 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jun 29 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Jun 23 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 05 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
May 05 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
May 05 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
